GlaxoSmithKline PLC (GSK, GSK.LN) reiterated the safety of its weight-loss drug alli Thursday, the same day it disclosed that alli was among the consumer products it plans to sell off.
It said orlistat, the active ingredient in alli, is the most-studied weight loss medicine, with its safety established in 100 clinical studies involving more than 30,000 patients. Glaxo said it "continues to proactively monitor for the safety of orlistat and share all relevant information with regulatory agencies."
In a bid to narrow its consumer health-care portfolio on fast-growing products and emerging markets, Glaxo said earlier Thursday that it plans to sell alli along with such other products as analgesics Solpadeine, BC and Goody's; vitamin and supplement product Abtei; and feminine-hygiene treatment Lactacyd.
Thursday, April 14, 2011
Glaxo Affirms Safety Of Alli After Unveiling Plans To Sell It - FoxBusiness.com
via foxbusiness.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment